<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05055297</url>
  </required_header>
  <id_info>
    <org_study_id>S2021_01</org_study_id>
    <nct_id>NCT05055297</nct_id>
  </id_info>
  <brief_title>SELUTION 014 BTK IDE Trial</brief_title>
  <official_title>SELUTION SLR™ 014 BTK: A Prospective Randomized Multicenter Single Blinded Study to Assess the Safety and Effectiveness of the SELUTION SLR™ 014 Drug Eluting Balloon in the Treatment of Below-the-Knee (BTK) Atherosclerotic Disease in Patients With Chronic Limb Threatening Ischemia (CLTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.A. Med Alliance S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.A. Med Alliance S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™&#xD;
      DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral&#xD;
      arterial disease (PAD) in the BTK arteries in CLTI patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 22, 2028</completion_date>
  <primary_completion_date type="Anticipated">September 11, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from target lesion occlusion, above-ankle amputation, or clinically driven target lesion re-intervention (CD-TLR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Major Adverse Limb Event (MALE) and all-cause perioperative death (POD)</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">377</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities</condition>
  <arm_group>
    <arm_group_label>SELUTION SLR™ DEB 014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Plain (Uncoated) Balloon Angioplasty (PTA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SELUTION SLR™ DEB 014</intervention_name>
    <description>a non-surgical procedure that uses a catheter to inflate a drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia</description>
    <arm_group_label>SELUTION SLR™ DEB 014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plain (Uncoated) Balloon Angioplasty (PTA)</intervention_name>
    <description>a non-surgical procedure that uses a catheter to inflate a commercially available, non-drug-eluting balloon to open up peripheral below-the-knee arteries that have been narrowed by chronic limb-threatening ischemia</description>
    <arm_group_label>Plain (Uncoated) Balloon Angioplasty (PTA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria:&#xD;
&#xD;
          1. Subject age is ≥ 18 years or older depending on local regulations.&#xD;
&#xD;
          2. Subject life expectancy is ≥ 1 year.&#xD;
&#xD;
          3. Subject has documented chronic limb-threatening ischemia in the target limb with&#xD;
             Rutherford classification category 4, 5 or 6 and symptoms of &gt; 2 weeks duration.&#xD;
&#xD;
          4. Subject is willing and able to provide written informed consent and comply with study&#xD;
             procedures and required follow-up evaluations.&#xD;
&#xD;
          5. Female subjects only: If female, then subjects of childbearing potential must be&#xD;
             non-breastfeeding and have a negative pregnancy test ≤ 7 days before the procedure and&#xD;
             be prepared to use effective contraception for 24 months after treatment.&#xD;
&#xD;
        Angiographic Inclusion Criteria:&#xD;
&#xD;
          1. Target lesion(s) must lie distal to the tibial plateau and above the tibiotalar joint&#xD;
             line within the BTK arteries. There is no limitation on total target lesion length.&#xD;
             Two in-line areas of stenosis are considered multiple lesions if a) there is 2 cm of&#xD;
             normal appearing artery between them, and b) at least 1 cm of the normal appearing&#xD;
             artery is not treated. Otherwise, the lesions should be considered a single lesion and&#xD;
             the entire segment should be treated with the assigned devices. If multiple SELUTION™&#xD;
             SLR DEB are used, the total allowable drug dose per patient by summing the drug dose&#xD;
             per individual balloons must be ≤ 4396μg.&#xD;
&#xD;
          2. Distal tibial and pedal runoff for each target lesion treated is patent (defined as&#xD;
             &lt;50% stenosis of the associated distal tibial artery and pedal outflow arteries).&#xD;
&#xD;
          3. Target vessel reference diameter(s) are ≥ 2mm and ≤ 4mm.&#xD;
&#xD;
          4. Arterial inflow (ipsilateral common iliac, external iliac, common femoral and profunda&#xD;
             femoris arteries, SFA and popliteal artery proximal to the tibial plateau) is free&#xD;
             from ≥ 50% stenosis as confirmed on angiography.&#xD;
&#xD;
               1. If ≥ 50% inflow stenosis of the common and external iliac, superficial femoral,&#xD;
                  and proximal popliteal arteries is found, it must be successfully treated during&#xD;
                  the index procedure.&#xD;
&#xD;
               2. Completion angiography must confirm successful treatment of inflow disease (≤30%&#xD;
                  residual stenosis, no distal embolization, and no Grade C or greater dissection )&#xD;
                  prior to pre-dilation and randomization of the BTK target lesion(s).&#xD;
&#xD;
          5. Successful pre-dilatation (defined by ≤ 30% residual stenosis, no distal embolization,&#xD;
             and no Grade C or greater dissection) of all target lesions with uncoated PTA catheter&#xD;
             sized to the reference vessel diameter must be accomplished before randomization.&#xD;
&#xD;
        Clinical Exclusion Criteria:&#xD;
&#xD;
          1. Subject underwent failed POBA intervention on the target lesion(s) within 3 months of&#xD;
             the index procedure.&#xD;
&#xD;
          2. Subject underwent surgical or endovascular procedure within 14 days prior to index&#xD;
             procedure, or is planned for surgical or endovascular procedure within 30 days&#xD;
             following index procedure, with the exception of:&#xD;
&#xD;
             a) Diagnostic angiography prior to index procedure b) Treatment of contralateral iliac&#xD;
             disease and/or treatment of inflow disease of the index limb that is completed prior&#xD;
             to randomization c) Planned amputation of digit(s) of the index limb at the phalangeal&#xD;
             level d) Debridement of a foot wound&#xD;
&#xD;
          3. Subject has infrainguinal disease in the contralateral leg that requires treatment at&#xD;
             the index procedure, or treatment planned to occur within 14 days prior to the index&#xD;
             procedure or within 30 days after the index procedure.&#xD;
&#xD;
          4. Subject is planned to undergo major amputation of either leg.&#xD;
&#xD;
          5. Subject has undergone any prior major amputation of the ipsilateral extremity.&#xD;
&#xD;
          6. Subject is unable to tolerate dual antiplatelet therapy.&#xD;
&#xD;
          7. Subject has undergone non-coronary artery treatment with any limus based drug-coated&#xD;
             or drug-eluting balloon/stent/other device within one year prior to index procedure.&#xD;
&#xD;
          8. Subject has undergone prior DCB, DES or BMS treatment of current target lesion(s).&#xD;
&#xD;
          9. Subject has known hypersensitivity or allergy to Sirolimus or other pharmacologic&#xD;
             agents (such as contrast agent, heparin, bivalirudin) required for the procedure, and&#xD;
             this hypersensitivity/allergy cannot be adequately pre-treated.&#xD;
&#xD;
         10. Subject has experienced stroke or MI within 3 months of index procedure.&#xD;
&#xD;
         11. Subject had onset of index limb symptoms less than 14 days prior to index procedure&#xD;
             (acute limb ischemia).&#xD;
&#xD;
        Subject has undergone prior bypass of arteries of the index limb (except for iliac artery&#xD;
        bypass).&#xD;
&#xD;
        13. Subject has non-atherosclerotic disease of the index limb (including aneurysmal&#xD;
        disease, vasculitis, Buerger's disease) 14. Subject has target lesion(s) that require&#xD;
        (pre-)treatment with alternative therapies such as thrombolysis, thrombus aspiration,&#xD;
        cutting/scoring/contoured balloon, stenting, laser, cryoplasty, brachytherapy,&#xD;
        intravascular lithotripsy, or re-entry device.&#xD;
&#xD;
        15. Subject has target lesion(s) that require treatment via pedal site. 16. Subject has&#xD;
        target lesion(s) that require access via upper extremity arteries.&#xD;
&#xD;
        17. Subject has extensive tissue loss salvageable only with complex foot reconstruction or&#xD;
        non-traditional trans metatarsal amputations. This includes subjects with:&#xD;
&#xD;
          1. Osteomyelitis involving, more proximal to, the metatarsal head(s)&#xD;
&#xD;
          2. Any heel wound or wound with calcaneal bone involvement&#xD;
&#xD;
          3. Wounds that are deemed to be neuropathic or non-ischemic in nature&#xD;
&#xD;
          4. Wounds that would require flap coverage or complex wound management for large soft&#xD;
             tissue defect&#xD;
&#xD;
          5. Full-thickness wounds on the dorsum of the foot with exposed tendon or bone&#xD;
&#xD;
          6. Venous or mixed wounds. 18. Subject has hypercoagulable state or disorder, or&#xD;
             coagulopathy, including platelet count less than 100,000 per microliter.&#xD;
&#xD;
             19. Subject has systemic infection (WBC &gt; 12,000 and febrile). [Note: Enrollment&#xD;
             permitted after successful treatment of infection with resolution of leukocytosis&#xD;
             and/or febrile state].&#xD;
&#xD;
             20. Subject has known immune compromise (e.g., HIV, SLE) or is receiving treatment&#xD;
             with immune suppressive medications.&#xD;
&#xD;
             21. Subject is receiving (or is scheduled to receive) cancer treatment with surgery or&#xD;
             chemotherapy or radiation therapy, or has metastatic malignancy.&#xD;
&#xD;
             22. Subject has acute renal insufficiency confirmed through 50% increase of serum&#xD;
             creatinine within 48 hours before procedure and/or decrease in urine output.&#xD;
&#xD;
             23. Subject with renal transplantation. 24. Subject has supplemental O2-dependent&#xD;
             COPD. 25. Subject has NYHA class IV congestive heart failure. 26. Subject has unstable&#xD;
             angina. 27. Subject is bedridden. 28. Subject has a body mass index (BMI) &lt; 18.&#xD;
&#xD;
             Angiographic Exclusion Criteria:&#xD;
&#xD;
               1. Presence of a previously placed stent in the target vessel(s), with the exception&#xD;
                  of:&#xD;
&#xD;
                    1. Target lesion located ≥30mm from stent, AND&#xD;
&#xD;
                    2. ≤ 30% in-stent-restenosis&#xD;
&#xD;
               2. Failure to successfully cross the target lesion.&#xD;
&#xD;
               3. Residual stenosis &gt; 30%, distal embolization, and Grade C or greater dissection&#xD;
                  after pre-dilatation of target lesion .&#xD;
&#xD;
               4. Intra-arterial thrombus, thromboembolism or atheroembolism in the index limb&#xD;
                  noted on initial diagnostic angiography or following treatment of inflow disease.&#xD;
&#xD;
               5. Requires treatment of the tibial arteries distal to the tibiotalar joint line, or&#xD;
                  treatment of the pedal arteries.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pedro Eerdmans</last_name>
    <phone>+41 (0)22 363 78 90</phone>
    <email>peerdmans@medalliance.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tamarah Suys</last_name>
    <email>tsuys@medalliance.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

